Although our study has characterized the pathological role of alternative FGFR1 splicing in breast cancer, further study is needed to determin if the FGFR isoforms can assist in idenfifying patients with FGFR-driven breast cancers and help therapeutic decision making. This evidence concerns the gene FGFR1 and breast carcinoma.